-- FDA feedback consistent with FDA’s preliminary communication in September-- --Company requesting meeting with FDA to discuss next steps required to resubmit the NDA-- FREMONT, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical
FREMONT, Calif. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company today announced that it has received a discipline review letter (DRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™
FREMONT, Calif. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the Cantor Virtual Global Healthcare Conference on
FREMONT, Calif. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the H.C.
FREMONT, Calif. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 15,937,130 shares of its common stock for gross proceeds of approximately $20.8 million,
FREMONT, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered
FREMONT, Calif. , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a feasibility study agreement with Mitsubishi Tanabe Pharma Corporation , a global pharmaceutical company that develops
Agreement outlines commercialization and distribution execution strategy upon FDA approval EVERSANA to provide commercial services of approximately $250 million over 5 years FREMONT, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
FREMONT, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2020 , as well as recent business highlights.
FREMONT, Calif. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday,
